This inventor holds 4 USPTO granted patents. Top assignees: Probiodrug Ag, Other. Active years: 2006-2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 73 
1 out of 834,513 Years Active: 2006-2012
Title: Innovations by Matthias Hoffmann in Neuropsychiatric Treatments
Introduction
Matthias Hoffmann is a notable inventor based in Wengelsdorf, Germany. He has made significant contributions to the field of neuropsychiatric treatments, holding a total of four patents. His work primarily focuses on the therapeutic applications of dipeptidyl peptidase IV inhibitors.
Latest Patents
Hoffmann's latest patents include innovative methods for treating schizophrenia and depression. One of his key inventions involves a method for therapeutically treating animals, including humans, for various psychosomatic, depressive, and neuropsychiatric diseases. This includes conditions such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm, and chronic pain. The administration of a suitable DP IV inhibitor leads to a reduction in the activity of the enzyme dipeptidyl peptidase, which in turn reduces the degradation of neuropeptide Y in the brain. This enhanced stability of neuropeptide Y results in prolonged activity, facilitating various neurological effects, including antidepressive and anxiolytic properties.
Another significant patent focuses on the treatment of anxiety using similar methods. The therapeutic approach aims to improve the stability and activity of neuropeptide Y, thereby providing relief from anxiety and other related conditions.
Career Highlights
Throughout his career, Matthias Hoffmann has worked with various companies, including Probiodrug AG. His innovative research has positioned him as a key figure in the development of new treatments for neuropsychiatric disorders.
Collaborations
Hoffmann has collaborated with notable professionals in his field, including Hans-Ulrich Demuth and Ants Kask. These collaborations have further enhanced the impact of his research and inventions.
Conclusion
Matthias Hoffmann's contributions to the field of neuropsychiatric treatments through his patents demonstrate his commitment to advancing medical science. His innovative approaches have the potential to significantly improve the quality of life for individuals suffering from various mental health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile